Hypertensive Nephropathy

Key Points

What Is Being Asked, and Why It Is Genuinely Contested

"Hypertensive nephropathy" carries an unusual epistemic burden: it is simultaneously one of the most frequently assigned renal diagnoses and one of the least frequently proven ones. The core problem is causal circularity—CKD of nearly any etiology raises blood pressure, so finding hypertension in a patient with declining GFR and a bland urinary sediment tells you very little about which came first. The literature has openly called the term "a term in quest of a disease."⁴ A common instinct is correct here: the honest answer is that some of it is real, much of it is a label of convenience.

Epidemiology — the "True Incidence" Problem

Assigned incidence. In USRDS accounting, hypertension is the second-most-common primary cause of incident ESRD (approximately 28–30%), behind diabetes (approximately 45–47%), with the attribution drawn from the CMS-2728 Medical Evidence form completed at dialysis initiation.¹ The racial signal is dramatic: ESRD incidence in Black Americans is roughly 3.8× that of White Americans, and hypertension is the most common assigned cause in Black patients, with historically approximately 5–6× the rate of hypertension-attributed ESRD versus non-Black patients.^1,5 Klag's 16-year MRFIT follow-up established a graded, dose-response relationship between baseline BP and subsequent ESRD across 332,544 men, which is the strongest population-level argument that BP is doing something causal.²

The problem with that number. The CMS-2728 attribution is a checkbox, not a diagnosis. It is filled in by the certifying nephrologist, typically without a biopsy, and defaults to "hypertension" when there is CKD + hypertension + no obvious alternative. This is precisely the mechanism by which a diagnosis of exclusion inflates its own incidence. The "true" incidence of biopsy-verifiable, genuinely hypertension-caused progressive nephropathy is unknown and certainly lower than the assigned figure.

Is It a Garbage-Bag Term? A Qualified Yes

Three independent lines of evidence say the label is over-applied:

The biopsy studies show clinicopathologic discordance

The AASK renal-biopsy pilot (Fogo et al.) is the most cited defense of the term—and it cuts both ways. In 88 hypertensive, non-diabetic Black patients without marked proteinuria, biopsies did mostly show the expected arteriolar/arterial sclerosis and glomerulosclerosis, with few surprise diagnoses (one mesangiopathic GN, one diabetic-pattern, two cholesterol emboli), which the authors read as validating the clinical diagnosis.⁵ But the same paper contains the finding that undermines the simple causal story: global glomerulosclerosis was extensive (mean 43 ± 26% of glomeruli) and its extent did not correlate with the degree of arteriolar or arterial thickening, though it did correlate with systolic BP, interstitial fibrosis, and 1/creatinine.⁵ If the vascular lesion were straightforwardly driving glomerular loss via downstream ischemia, those should track together. They don't—foreshadowing a glomerular (later, genetic) driver. Contemporary registry work echoes this: the Japan Renal Biopsy Registry documents substantial clinicopathological discordance in biopsy-labeled "nephrosclerosis."⁶

APOL1 reassigned much of what we called hypertensive nephrosclerosis

This is the decisive development. Genovese et al. (2010) showed that two coding variants (G1, G2) in APOL1 on chromosome 22—common on African chromosomes, absent from European ones—are strongly associated with FSGS (OR approximately 10.5) and, critically, with hypertension-attributed ESKD (OR approximately 7.3).⁷ Kopp et al. extended this to FSGS and HIV-associated nephropathy.⁸ Then Parsa et al. (2013) closed the loop in the very cohort that defined the field: among 693 Black AASK participants with CKD "attributed to hypertension," those with the APOL1 high-risk genotype reached the composite renal endpoint in 58.1% vs 36.6% for the low-risk group (HR 1.88, p<0.001), with no interaction with baseline proteinuria.⁹ In other words, a large share of "hypertensive nephrosclerosis" in Black patients is a genetically driven, FSGS-spectrum nephropathy in which hypertension is the accompaniment, not the etiology.^9,10 This is why "APOL1-associated nephropathy" has largely displaced "hypertensive nephrosclerosis" as the operative diagnosis in high-risk-genotype patients.

The term is defined by absence, not presence

Historically the diagnosis requires long-standing hypertension, reduced GFR, minimal proteinuria, bland sediment, and no other identifiable cause—i.e., a diagnosis by subtraction.^3,4 Any diagnosis defined by what is missing will absorb whatever occult disease escapes a non-invasive workup.

What is genuinely real

• Malignant nephrosclerosis — unambiguously causal, biopsy-defined, and reproducible in animal models above a critical BP threshold.¹⁵ No controversy here.
• Benign arteriolar nephrosclerosis — the hyaline arteriolar and small-artery sclerosis of chronic hypertension is a real, near-universal age- and BP-associated finding; the controversy is not whether it exists but whether, in any given patient, it is sufficient to cause ESRD as opposed to being an ischemic epiphenomenon of aging vasculature.^3,4

Pathophysiology and the Autoregulation Paradox

The core question is this: if the afferent arteriole autoregulates, how does systemic pressure ever reach the glomerulus?

The afferent arteriole really does protect the glomerulus

Renal autoregulation holds RBF and single-nephron GFR roughly constant across MAP approximately 80–160 mmHg via two preglomerular mechanisms: the myogenic response (afferent constriction to increased wall tension; fast, and the dominant protector against pressure) and tubuloglomerular feedback (macula-densa NaCl sensing → adenosine-mediated afferent tone; slower).¹⁴ Because these act upstream of the glomerulus, they attenuate transmission of systemic pressure to the glomerular capillary. In animals with intact autoregulation, even substantial hypertension produces little glomerulosclerosis.^11,12

So damage requires that this protection fail—by one of two routes

The Bidani–Griffin framework, built on conscious-animal radiotelemetry, resolves the paradox cleanly:^11,12

• Route A — exceeding the ceiling. When BP rises above the upper limit of autoregulation, the afferent can no longer hold; pressure breaks through to the glomerulus → endothelial barotrauma, fibrinoid necrosis, and malignant nephrosclerosis. This is threshold-dependent: below the critical MAP, injury is minimal; above it, severe.^12,15
• Route B — impaired autoregulation (the common, chronic route). In CKD, diabetes, states of reduced nephron mass/hyperfiltration, and—by inference—APOL1 disease, preglomerular autoregulatory capacity is itself impaired. The afferent is relatively vasodilated or unresponsive, so it no longer buffers pressure. Now even moderate BP is transmitted to the glomerulus, glomerular hypertension and hyperfiltration ensue, and glomerulosclerosis increases roughly linearly with BP, on a steeper slope and at a much lower threshold than in the intact kidney.^11,12

The single most important clinical corollary follows directly: in patients whose autoregulation is already impaired (i.e., established CKD/diabetes), BP must be lowered into the normotensive range to protect the glomerulus, because there is no preglomerular buffer left to do so.¹¹

Two coexisting glomerular lesions

Chronic hypertensive kidneys typically show a mixture: (a) ischemic obsolescence—wrinkled, collapsed capillary tufts with capsular fibrosis, downstream of narrowed hyaline arterioles; and (b) secondary FSGS—segmental sclerosis from glomerular hypertension in relatively spared nephrons that hyperfilter to compensate. The Fogo finding that glomerulosclerosis tracked with systolic BP but not with arteriolar thickening is most consistent with a hyperperfusion/hyperfiltration (route B) mechanism operating alongside, or instead of, pure ischemia.⁵

Arteriolar Hypertrophy: Is It the Injury, and Does It Reverse?

A subtle point here is that the media response is not monolithic—its components have opposite implications.

Muscular hypertrophy is mostly protective, not the lesion

Increased preglomerular (afferent + interlobular) resistance from medial thickening is precisely what shields the glomerulus by raising the pressure drop upstream. Interpreted through the autoregulation model, adaptive medial thickening is part of the defense, not the damage.^11,13 The damage arises when this crosses into:

• Hyaline arteriolosclerosis — insudation of plasma proteins into the wall, producing a homogeneous, glassy, acellular thickening that narrows the lumen. This causes downstream ischemia and—critically—converts the vessel into a rigid tube that loses its autoregulatory (myogenic) responsiveness, re-opening route B. Hyalinosis is thus doubly bad: ischemia plus loss of the protective reflex.^11,14 It is also degenerative and essentially irreversible.
• Glomerular barotrauma / secondary FSGS — from pressure that the failed autoregulation no longer buffers.

What regresses with BP control, and what doesn't

This maps onto Mulvany's remodeling taxonomy:

Schiffrin's subcutaneous-resistance-artery biopsy studies are the human proof of principle: after 1–2 years, the ACE inhibitor cilazapril progressively normalized the media-to-lumen ratio of small arteries, whereas atenolol produced no change despite equivalent BP reduction.¹⁶ The implication is that adaptive vascular remodeling has a component that is angiotensin-II-driven and pressure-independent, and therefore preferentially reversible with RAAS blockade rather than BP lowering per se.

Even severe lesions can repair—if BP is controlled below the threshold

In a malignant-nephrosclerosis rat model, Griffin et al. showed the injury is sharply BP-threshold-dependent and that established microvascular and glomerular injury can undergo genuine repair once BP is brought below the critical level.¹⁵ This is the mechanistic underpinning of the clinical observation that some patients recover meaningful renal function months after malignant hypertension is controlled.

Onion-Skinning

"Onion-skin" (or onion-skinning) is hyperplastic arteriolosclerosis: concentric, laminated layers of proliferating myointimal smooth-muscle cells and reduplicated basement membrane encircling the interlobular arteries and afferent arterioles, producing severe, often near-obliterative luminal narrowing on cross-section—the layered "onion bulb" appearance. It is the vascular signature of malignant / accelerated hypertension, typically accompanied in the acute phase by fibrinoid necrosis of the arteriolar wall and glomerular tuft.¹⁵

Contrast the two arteriolar patterns explicitly:

Bottom Line for Practice

1. Incidence: The approximately 28–30% "hypertension" share of incident ESRD is an administrative attribution, not a verified pathological incidence; the true causal incidence is lower and unknown.¹
2. Garbage-bag question: Substantially yes—especially in Black patients, where APOL1 and occult glomerular disease account for much of it^5,7,9—but a real core exists (malignant nephrosclerosis always; benign arteriolar nephrosclerosis often as contributor).
3. Autoregulation paradox: The afferent does protect. Chronic injury requires either exceeding the autoregulatory ceiling (malignant) or losing autoregulation (CKD/diabetes/low nephron mass/APOL1), after which glomerulosclerosis rises linearly with BP.^11,12
4. Arteriolar remodeling: Muscular/eutrophic hypertrophy is protective and reversible (RAAS blockade > β-blocker); hyalinosis and glomerulosclerosis are fixed. Acute barotraumatic lesions can repair below the BP threshold.^15,16
5. Onion-skinning: Hyperplastic arteriolosclerosis of malignant HTN; always consider the TMA differential.

References

1. United States Renal Data System. 2024 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. Bethesda, MD: NIDDK, NIH; 2024. (Summary: Am J Kidney Dis. 2025.)
2. Klag MJ, Whelton PK, Randall BL, et al. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA. 1997;277(16):1293–1298.
3. Freedman BI, Iskandar SS, Appel RG. The link between hypertension and nephrosclerosis. Am J Kidney Dis. 1995;25(2):207–221.
4. Meyrier A. Nephrosclerosis: a term in quest of a disease. Nephron. 2015;129(4):276–282. doi:10.1159/000381195
5. Fogo A, Breyer JA, Smith MC, et al; AASK Pilot Study Investigators. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. Kidney Int. 1997;51(1):244–252. doi:10.1038/ki.1997.29
6. Sumida K, Takeda A, Furuichi K, et al. Clinicopathological discordance in biopsy-proven nephrosclerosis: a nationwide cross-sectional study of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2022;26(4):325–332.
7. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329(5993):841–845. doi:10.1126/science.1193032
8. Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22(11):2129–2137. doi:10.1681/ASN.2011040388
9. Parsa A, Kao WHL, Xie D, et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013;369(23):2183–2196. doi:10.1056/NEJMoa1310345
10. Freedman BI, Kopp JB, Langefeld CD, et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol. 2010;21(9):1422–1426.
11. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension. 2004;44(5):595–601. doi:10.1161/01.HYP.0000145180.38707.84
12. Griffin KA, Bidani AK. Hypertensive renal damage: insights from animal models and clinical relevance. Curr Hypertens Rep. 2004;6(2):145–153. doi:10.1007/s11906-004-0091-8
13. Bidani AK, Griffin KA, Williamson G, Wang X, Loutzenhiser R. Protective importance of the myogenic response in the renal circulation. Hypertension. 2009;54(2):393–398. doi:10.1161/HYPERTENSIONAHA.109.133777
14. Carlström M, Wilcox CS, Arendshorst WJ. Renal autoregulation in health and disease. Physiol Rev. 2015;95(2):405–511. doi:10.1152/physrev.00042.2012
15. Griffin KA, Polichnowski A, Litbarg N, et al. Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant nephrosclerosis model. Hypertension. 2014;64(4):801–807. doi:10.1161/HYPERTENSIONAHA.114.03609
16. Schiffrin EL, Deng LY, Larochelle P. Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension. 1994;23(1):83–91. doi:10.1161/01.hyp.23.1.83
17. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421–2431.
18. Appel LJ, Wright JT Jr, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363(10):918–929. doi:10.1056/NEJMoa0910975